Printed From:

How Lantus® Compares at Helping Patients Achieve Glycemic Targets

Lantus® long-acting insulin can provide effective, improved glycemic control in diabetes patients as part of an overall diabetes treatment plan, which includes diet, exercise, and other diabetes medications.1

Registration Trial

Lantus® + OADs vs NPH + OADs in Patients With Type 2 diabetes2,3
  • Study designed to compare efficacy and safety of Lantus® and NPH

Study Design

In a 52-week study, 570 patients with type 2 diabetes poorly controlled by OADs were randomized to either Lantus® (n=289) or NPH (n=281) at bedtime to reach a target FBG of <120 mg/dL. OADs were continued. Initial insulin dose and titration schedule was left to the discretion of the individual investigators. Primary endpoint was change in A1C.2,3

  • 0.5% mean A1C reduction at 52 weeks2
From Yki-Järvinen,3 data on file,2 and Lantus® Prescribing Information.1
  • Lantus® dose at 52 weeks: 26 Units (range 3-120 Units)

Safety Results1,2

An appropriate dose and proper titration helped many patients achieve glycemic targets

Study Design

Data from a 24-week, multicenter, randomized, parallel, open-label trial of 756 overweight men and women compared the abilities and associated hypoglycemic effects of Lantus® added to prestudy OADs (n=367) vs NPH added to prestudy OADs (n=389) in insulin-naïve patients with type 2 diabetes and inadequate glycemic control (A1C >7.5%) on 1 or 2 oral agents (sulfonylureas, metformin, or thiazolidinediones) and treated to a target FPG ≤ 100 mg/dL. Lantus® or NPH was administered once daily at bedtime. Primary endpoint was percentage of patients achieving A1C ≤ 7.0% without a single instance of symptomatic nocturnal hypoglycemia.

From Riddle4 and data on file.2
  • 1.7% mean A1C reduction at 24 weeks2,4
  • 58% of patients randomized to Lantus® achieved A1C ≤7%4
From Riddle4 and data on file.2
  • Titration is required to achieve FPG target4
  • Titration to appropriate fasting glucose target is necessary to help achieve glycemic goals
  • Lantus® dose at study end: 47 Units (range 10-144 Units)

Safety Results2,4


  1. Lantus® Prescribing Information. February 2015.
  2. Data on file, Sanofi U.S. LLC.
  3. Yki-Järvinen H, Ziemen M, Dressler A; HOE 901/3002 Study Group. Diabetes Care. 2000;23(8):1130-1136.
  4. Riddle MC, Rosenstock J, Gerich J, on behalf of the Insulin Glargine 4002 Study Investigators. Diabetes Care. 2003;26:3080-3086.

Proven HbA1c control

See how Lantus® provides effective, improved glycemic control in diabetes patients.

Lantus® Prescribing Information. February 2015.

Once-daily dosing

Lantus® is a once-daily, long-acting insulin.**

**Lantus® Prescribing Information. February 2015.

Demonstrated long-term CV safety

Lantus® is a basal insulin with demonstrated long-term CV safety data††

††Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure. No difference was observed between Lantus® and standard of care in overall incidence of CV death, nonfatal MI, or nonfatal stroke. No difference was observed between treatment groups for death of any cause.